National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedKemme S, Stahl M, Brigham D
Outcomes of severe seronegative hepatitis-associated aplastic anemia: a pediatric case series.
Hepatitis-associated aplastic anemia (HAAA) is a potentially life-threatening diagnosis without clear treatment guidelines. The goal of the study was to characterize the presentation, evaluation, histopathology, and outcomes of therapy in children with HAAA to guide future research and to develop standardized care guidelines for this rare disease. The investigators found that ATG-based IST induced remission of hepatitis in patients with steroid-refractory HAAA.
AHRQ-funded; HS026510.
Citation: Kemme S, Stahl M, Brigham D .
Outcomes of severe seronegative hepatitis-associated aplastic anemia: a pediatric case series.
J Pediatr Gastroenterol Nutr 2021 Feb;72(2):194-201. doi: 10.1097/mpg.0000000000002940..
Keywords: Children/Adolescents, Hepatitis, Patient-Centered Outcomes Research, Outcomes, Evidence-Based Practice, Guidelines
Pho MT, Jensen DM, Meltzer DO
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
The researchers developed a decision model to quantify the trade-offs between immediate, interferon-containing therapy and delayed, interferon-free therapy for patients with chronic, genotype 1 HCV infection. They found that compared to one-time immediate treatment with the interferon-containing regimen, delayed treatment with the interferon-free regimen in 1 year resulted in longer life expectancy.
AHRQ-funded; HS022433.
Citation: Pho MT, Jensen DM, Meltzer DO .
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
J Viral Hepat 2015 Aug;22(8):630-8. doi: 10.1111/jvh.12412..
Keywords: Clinical Decision Support (CDS), Shared Decision Making, Hepatitis, Medication, Outcomes
Montenovo MI, Dick AA, Hansen RN
Donor hepatitis C sero-status does not impact survival in liver transplantation.
The researchers sought to assess the impact of both donor and recipient HCV status on patient and graft survival. They found that the use of HCV+ grafts in HCV+ recipients is not associated with worse outcomes. They conclude that with the increase in HCV+patients awaiting an organ, more consideration should be given to HCV+ donors.
AHRQ-funded; HS021686.
Citation: Montenovo MI, Dick AA, Hansen RN .
Donor hepatitis C sero-status does not impact survival in liver transplantation.
Ann Transplant 2015 Jan 22;20:44-50. doi: 10.12659/aot.892530..
Keywords: Hepatitis, Comparative Effectiveness, Outcomes, Mortality